6P Response and survival according to the interferon-gamma (IFN-γ) signature and tumor mutational burden (tmb) in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
| Autor: | Reijers, Dimitriadis, P., Traets, J.J., Saw, R., Versluis, J.M., Pennington, T., Kapiteijn, E., Van der Veldt, A.A.M., Suijkerbuijk, K., Hospers, G., Van Houdt, W., Broeks, A., Cornelissen, S., Spillane, A., Scolyer, R., van de Wiel, B., Menzies, A.M., van Akkooi, A.C.J., Long, G.V., Blank, C.U. |
|---|---|
| Zdroj: | In Immuno-Oncology and Technology December 2022 16 Supplement 1 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|